RT Journal Article
SR Electronic
T1 Analysis of SARS-CoV-2 Variant-Specific Serum Antibodies Post-Vaccination Utilizing Immortalized Human Hepatocyte-like Cells (HLC) to Assess Development of Protective Immunity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.08.23293863
DO 10.1101/2023.08.08.23293863
A1 Collins, Daniel P
A1 Steer, Clifford J
YR 2023
UL http://medrxiv.org/content/early/2023/08/13/2023.08.08.23293863.abstract
AB Background Our previous studies demonstrated that SARS-CoV-2 spike proteins could bind to hepatocytes via the asialoglycoprotein receptor-1 (ASGR-1) facilitating direct infection by the SARS-CoV-2 virus. Immortalized E12-HLC expressed the phenotypic and biological properties of primary human hepatocytes, including their ability to bind spike proteins via ASGR-1 with exception of the spike 1 protein. This binding could be inhibited by spike protein-specific monoclonal antibodies. We used the same spike-blocking analysis to determine if post-vaccination serum was capable of blocking spike protein binding to HLC. Samples collected from subjects prior to, and post-vaccination were quantified for anti-variant-specific antibody (original wild type, alpha (α), beta (β), gamma (γ) and delta (δ) variants) by a flow cytometry based immunofluorescent assay. Inhibition of variant spike protein binding to HLC and AT-2 (as a known model for spike 1 binding to the ACE-2 receptor) was analyzed by confocal microscopy. This study was designed to investigate the ability of post-vaccination antibodies to mediate immunity to spike S2, and to validate the utility of the E12-HLC in analyzing that immunity.Methods Serum was collected from 10 individuals pre- and post-vaccination with the J&J, Moderna or Pfizer vaccines. The serum samples were quantified for variant-specific antibodies in a flow cytometry-based immunofluorescent assay utilizing beads coated with biotinylated variant spike proteins (α, β, γ, δ). Presence of variant-specific antibodies was visualized by anti-human IgG-Alexa 488. Inhibition of spike protein binding to cells was analyzed by immunofluorescent confocal analysis. Biotinylated variant spike proteins were preincubated with serum samples and then tested for binding to target cells. Binding was visualized by Streptavidin-Alexa 594. Results were compared to binding of unblocked spike variants.Results All variant spike proteins tested bound to both the HLC and AT-2 cells. Pre-vaccination serum samples had no detectable reactivity to any of the variant spike proteins and were unable to inhibit binding of the variant spike proteins to either target cell. Post-vaccination serum samples demonstrated a progression of SARS-CoV-2 antibody levels from low early post-vaccination levels to higher levels at 2.5 months after vaccination. Concurrently, serum samples taken at those different timeframes demonstrated that serum obtained from shortly after vaccination were not as effective in blocking spike protein as serum obtained after 2.5 months post-vaccination. Antibody concentrations were not necessarily associated with better blocking of spike protein binding as spike variant-specific serum antibody concentrations varied significantly between subjects and within each subject. It was also demonstrated that vaccination with all the various available vaccines stimulated antibodies that inhibited binding of the available variant spike proteins to both HLC and AT-2 cells.Conclusion HLC, along with AT-2 cells, provides a useful platform to study the development of protective antibodies that prevent the binding SARS-CoV-2 spike proteins to target cells. It was shown that vaccination with the three available vaccines all elicited serum antibodies that were protective against binding of each of the variant spike proteins to both AT-2 and HLC cells. This study suggests that analysis of immune serum to block spike binding to target cells may be a more useful technique to assess protective immunity than quantitation of gross antibody alone.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by CMDG, LLC.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Cells that were generated (MLPC, HLC and AT-2) and other tissues (cord blood and peripheral blood samples) used in this study received IRB approval by the Quorum Review Protocol #800, March 3, 2005. Donations were collected with donor consent for research use only.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript